Mycophenolat Mofetil Tillomed (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolat Mofetil Tillomed, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent rejection of transplanted organs and to treat lupus nephritis in adult patients. GNH USA supplies Mycophenolat Mofetil Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in conditions where immune suppression is required to protect transplanted tissue or control autoimmune kidney disease.

Kidney transplant: helps prevent acute and chronic graft rejection. Heart transplant: reduces the risk of organ rejection after surgery. Lupus nephritis: improves renal function and reduces proteinuria in patients with systemic lupus erythematosus.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset (nausea, diarrhea, abdominal pain). - Hematologic changes (leukopenia, anemia, thrombocytopenia). - Headache or dizziness. - Elevated liver enzymes.

Serious or Rare Side Effects: - Opportunistic infections (e.g., cytomegalovirus, fungal infections). - Progressive multifocal leukoencephalopathy (PML). - Severe hypersensitivity reactions (rash, Stevens‑Johnson syndrome). - Pregnancy‑related teratogenicity and fetal loss.

Before initiating therapy, clinicians should assess baseline laboratory values and consider patient‑specific risk factors.

Monitor blood counts: perform regular CBC to detect leukopenia or anemia. Assess renal function: adjust therapy if creatinine clearance declines. Avoid use in pregnancy: drug is contraindicated (Category X). Screen for infections: treat active infections before starting. Consider hepatic impairment: dose may need adjustment. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Mycophenolate Mofetil interacts with several agents that can alter its exposure or increase infection risk.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption of mycophenolic acid. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower drug levels.

Moderate Interactions (Monitor Closely): - Azathioprine or other myelosuppressants: increase risk of bone‑marrow suppression. - Live vaccines: may cause uncontrolled infection. - Concomitant nephrotoxic agents (e.g., calcineurin inhibitors): require renal function monitoring.